Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Tr

  Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro,        Which Received FDA Approval Late Last Year for the Treatment of                         Hyperphosphatemia in Dialysis  Interest in GCS-100, Velcalcetide, ST-10, GSK-1278863A and Rayaldee Ranges from Moderate to High, According to Findings from Decision Resources Group  PR Newswire  BURLINGTON, Mass., July 10, 2014  BURLINGTON, Mass., July 10, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of surveyed nephrologists report awareness of the U.S. Food and Drug Administration's (FDA) approval of Vifor Fresenius Medical Care Renal Pharma's new phosphate binder Velphoro, which was approved by the FDA in November 2013 for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.  Decision Resources Group Logo.  Other key findings from the report entitled TreatmentTrends: Nephrology (US) Q2 2014:    oBundling: Based on mean ratings, surveyed nephrologists are under the most     pressure from their dialysis unit to restrict measurement of nonessential     labs, to use lower doses of erythropoiesis-stimulating agents (ESAs) and     to have more stringent hemoglobin targets resulting in less ESA use.     Surveyed nephrologists believe that the delay of inclusion of oral     dialysis drugs into the end-stage renal disease payment bundle will     similarly impact future use of phosphate binders, oral iron and Amgen's     Sensipar.   oIV Iron patient share in hemodialysis (HD): American Regent/Fresenius     Medical Care's Venofer has significantly declined in reported HD patient     share compared with this time period last year.   oNephrologists' perceptions of late-stage compounds in clinical     development: The report discusses aided familiarity, interest and     percentage of patients as likely candidates for 12 renal products in     development after review of product profiles. New product profiles added     to this quarter's report, include:         oLaJolla Pharmaceutical's GCS-100: Nearly half of nephrologists report          high interest in the product, which was higher than all other renal          anemia and bone mineral metabolism products in late-stage development          covered in this study.        oGSK's GSK-1278863A: Nearly one-third of nephrologists report high          interest in this oral renal anemia product.        oShield Therapeutics' ST-10: Nearly a third of nephrologists report          high interest in this oral ferric iron therapy.        oAmgen's Velcalcetide: Should this intravenous therapy for secondary          hyperparathyroidism (SHPT) receive FDA approval, nephrologists expect          significantly higher usage in the dialysis versus the CKD          non-dialysis (ND) setting.        oOPKO Health's Rayaldee: While familiarity is low, over 40 percent of          nephrologists report high interest in this oral Vitamin D therapy          used to treat SHPT being tested in CKD stage 3 and stage 4 patients,          after review of a product profile.  Comments from Decision Resources Group Director Rob Dubman:    o"Physicians are recalling lower number of pills as one of Velphoro's     primary messages from sales representatives. Not surprisingly, we have     found that in this and other studies that delivery attributes are not as     important compared with efficacy and safety attributes."  Additional Resources:  A special report that is expected to publish later this month entitled The Impact of New Iron-Based Phosphate Binders on the Hyperphosphatemia Market will also help manufacturers understand why and how Velphoro and Keryx Pharmaceutical's Zerenex will be used, if Zerenex receives FDA approval later this year.  About Decision Resources Group Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.  All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.  For more information, contact:  Decision Resources Group Christopher Comfort 781-993-2597 ccomfort@dresourcesgroup.com  Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO  SOURCE Decision Resources Group  Website: http://www.DecisionResourcesGroup.com  
Press spacebar to pause and continue. Press esc to stop.